Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cyclosilicate

- PMLiVE

AZ prepares to file COPD triple, taking on rival GSK

Latest salvo in combination trials competition

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

- PMLiVE

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

European approvals for Amgen and AstraZeneca

AstraZeneca AZ

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Its combo missed two of the main endpoints of the study

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

AstraZeneca AZ

AstraZeneca joins Merck in Brexit stockpiling effort

Says it is increasing stores of medicines by around 20%

AstraZeneca AZ

AZ makes gene therapy move with 4DMT alliance

The new partnership will focus on creating an AAV for lung disease

- PMLiVE

30 Women Leaders in UK Healthcare

The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future

- PMLiVE

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Another BACE candidate is abandoned, leaving just one remaining in the pipeline

- PMLiVE

Daily Brief: Tagrisso’s first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS

A rapid round up of today's pharma, biotech and healthcare news

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Daily Brief: AstraZeneca’s new San Fran home, Keytruda triumphs again, Novo branches out

A rapid round up from pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links